This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

TearLab Announces Issuance Of Core U.S. Patent

SAN DIEGO, Oct. 13, 2010 (GLOBE NEWSWIRE) -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today announced that it has been granted U.S. Patent No. 7,810,380, entitled "Systems and methods for collecting tear film and measuring tear film osmolarity." This patent provides the company with broad and blocking intellectual property regarding the measurement of genetic and protein biomarkers within the tear film.

The patent, which will expire in 2029, allows TearLab to build upon its non-invasive tear collection platform to explore biomarkers across a wide range of disease states. This includes, but is not limited to, the Company's initial commercial target of Dry Eye Disease.

"The key to this patent is that it covers the simultaneous measurement of tear osmolarity, which represents the fundamental piece of information needed for high-quality quantification of components of tears," commented Benjamin Sullivan, Ph.D., TearLab's Chief Scientific Officer. "As people age, their tear film becomes more porous, and the concentration fluctuates significantly at each blink due to water loss through an unstable tear film. For instance, if an individual's glucose measurement is twice as concentrated because of evaporation through an unstable tear film, it does not necessarily mean they have high blood sugar. It could just be that their lacrimal gland isn't producing enough tear fluid. And because normal tear osmolarities are held within a very tight range, the simultaneous measurement of osmolarity allows us to set a baseline to which we can accurately compare patient to patient, without the significant variance induced by biological osmolarity variance."

Dr. Sullivan concluded, "TearLab's expertise in performing assays in 50 nL of fluid has also shown that the real-time measurement of tear osmolarity allows our lab-on-a-chip approach to compensate for the effects of evaporation during sample transfer, which can change the value of a diagnosis in less than five seconds at such a small volume."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs